Kezar Life Sciences estimates $307M cash, cash equivalents and marketable securities as of June 30, 2022

Kezar Life Sciences, Inc.

Preliminary cash, cash equivalents and marketable securities balance of approximately $307 million as of June 30, 2022.
Estimate is unaudited and subject to quarter-end closing adjustments.
No other financial results for Q2 2022 provided; comprehensive statement not yet available.
Company emphasizes this is a preliminary estimate and not a complete financial report.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.